Skip to main content
. 2019 Mar 1;19:100464. doi: 10.1016/j.ymgmr.2019.100464

Fig. 2.

Fig. 2

A: Longitudinal trend in the percentage of clinical NGS reports with VUS and the number of genes tested (2012–2017): The proportion of reports with variants of uncertain significance (VUS) decreased from 50.70% in 2012 to 22.12% in 2017 (solid bars) while the average number of genes analyzed per report increased during the same time period from 8 genes/panel in 2012 to 25 genes/panel in 2017 (dotted line), with the largest increase in genes/panel happening in 2014 due to the change from the SureSelect capture panel (Agilent Inc.) to the TruSight One panel (Illumina Inc.). B: Number of VUS reported per gene analyzed, the number of VUS identified per gene analyzed decreased 0.19 VUS reported per gene analyzed in 2012 to 0.03 VUS reported per gene analyzed in 2017.

1 = SureSelect NGS panel (Agilent Inc.)

2 = Trusight One targeted NGS panel (Illumina Inc.)

3 = TruSight One NGS panel (Illumina Inc.)